| Literature DB >> 28671630 |
Reina Engle-Stone1, Thomas N Williams2, Martin Nankap3, Alex Ndjebayi4, Marie-Madeleine Gimou5, Yannick Oyono6, Ann Tarini7, Kenneth H Brown8,9, Ralph Green10.
Abstract
Information on the etiology of anemia is necessary to design effective anemia control programs. Our objective was to measure the prevalence of inherited hemoglobin disorders (IHD) in a representative sample of children in urban Cameroon, and examine the relationships between IHD and anemia. In a cluster survey of children 12-59 months of age (n = 291) in Yaoundé and Douala, we assessed hemoglobin (Hb), malaria infection, and plasma indicators of inflammation and micronutrient status. Hb S was detected by HPLC, and α⁺thalassemia (3.7 kb deletions) by PCR. Anemia (Hb < 110 g/L), inflammation, and malaria were present in 45%, 46%, and 8% of children. A total of 13.7% of children had HbAS, 1.6% had HbSS, and 30.6% and 3.1% had heterozygous and homozygous α⁺thalassemia. The prevalence of anemia was greater among HbAS compared to HbAA children (60.3 vs. 42.0%, p = 0.038), although mean Hb concentrations did not differ, p = 0.38). Hb and anemia prevalence did not differ among children with or without single gene deletion α⁺thalassemia. In multi-variable models, anemia was independently predicted by HbAS, HbSS, malaria, iron deficiency (ID; inflammation-adjusted ferritin <12 µg/L), higher C-reactive protein, lower plasma folate, and younger age. Elevated soluble transferrin receptor concentration (>8.3 mg/L) was associated with younger age, malaria, greater mean reticulocyte counts, inflammation, HbSS genotype, and ID. IHD are prevalent but contribute modestly to anemia among children in urban Cameroon.Entities:
Keywords: anemia; children; hemoglobinopathy; iron; sickle cell; thalassemia
Mesh:
Substances:
Year: 2017 PMID: 28671630 PMCID: PMC5537808 DOI: 10.3390/nu9070693
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Characteristics of children 12–59 months of age in Yaoundé and Douala, Cameroon 1.
| Variable | Value |
|---|---|
| Age, months | 32.8 ± 0.8 |
| Male, | 155 (50) |
| Breastfeeding, | 11 (4) |
| Stunted (HAZ < −2), % | 15.6 ± 2.4 |
| Wasted (WHZ < −2), % | 1.4 ± 0.7 |
| Inflammation (CRP > 5 mg/L and/or AGP > 1 g/L), % | 46.4 ± 3.1 |
| Malaria, % | 8.0 ± 2.1 |
| Hemoglobin, g/L | 110 ± 1 |
| Anemia (Hb < 110 g/L), % | 45.4 ± 2.9 |
| Severe anemia (Hb < 70 g/L), % | 1.0 ± 0.5 |
| Reticulocytes, cells/µL | 47,000 ± 2000 |
| Reticulocytes, cells/µL 2 | 39,000 (29,000, 54,000) 2 |
| Reticulocytes > 150,000 cells/µL, | 5 (1.7) |
| Unadjusted ferritin, µg/L | 51.1 ± 2.8 |
| Adjusted ferritin 3, µg/L | 32.2 ± 1.2 |
| Adjusted Ferritin 3 < 12 µg/L, % | 13.2 ± 2.0 |
| sTfR, mg/L | 8.22 ± 0.20 |
| sTfR > 8.3 mg/L, % | 25.4 ± 2.3 |
| Unadjusted RBP, µmol/L | 0.88 ± 0.02 |
| Adjusted RBP 3, µmol/L | 1.06 ± 0.01 |
| Adjusted RBP 3 < 0.83 umol/L, % | 13.5 ± 1.9 |
| Plasma zinc, µg/dL | 66.8 ± 1.6 |
| Adjusted plasma zinc 3, µg/dL | 74.0 ± 1.7 |
| Low adjusted plasma zinc 3,4, % | 23.2 ± 3.8 |
| Folate, nmol/L | 56.0 ± 2.1 |
| Plasma B12, pmol/L | 851 ± 51 |
1 Values are mean or % ± SE or n (%), unless otherwise indicated; n = 278–302, depending on the indicator. AGP, alpha-1-acid glycoprotein; CRP, C-reactive protein; HAZ, height-for-age Z-score; Hb, hemoglobin; sTfR, soluble transferrin receptor, WAZ, weight-for-age Z-score; WHZ, weight-for-height Z-score. 2 Median (25th percentile, 75th percentile). 3 Values adjusted for inflammation by regression analysis to values equivalent to those at CRP and AGP concentrations of 0.14 mg/L CRP and 0.52 g/L AGP (the 10th percentile among individuals with CRP < 5 and AGP < 1). 4 Low plasma zinc defined as <65 µg/dL for morning samples and <57 µg/dL for afternoon samples [23], after adjusting for inflammation as noted above.
Prevalence of inherited hemoglobin disorders among a representative sample of children 12–59 months of age in Yaoundé and Douala, Cameroon 1.
| Urban Total | Yaoundé | Douala | ||
|---|---|---|---|---|
| Any Hb S or alpha-globin 2 deletion | 42.9 (37.4–48.4) | 48.9 (39.7–58.1) | 37.1 (30.1–44.0) | |
| Sickle cell disease or trait 3 | ||||
| HbSS | 1.6 (0.2–3.0) | 2.7 (0.1–5.3) | 0.6 (0–1.9) | |
| HbAS | 13.7 (9.7–17.8) | 12.6 (6.3–18.9) | 14.8 (9.1–20.5) | |
| α+-thalassemia 2 | ||||
| Homozygous (–α/–α) | 3.1 (1.1–5.2) | 4.9 (1.2–8.6) | 1.4 (0–3.5) | |
| Heterozygous (–α/αα) | 30.6 (25.4–35.8) | 37.0 (27.7–46.4) | 24.4 (18.9–29.9) | |
| Other Hb conditions 3 | ||||
| Increased F | 4.7 (2.7–6.6) | 5.5 (2.5–8.4) | 3.9 (1.2–6.7) |
1 Values are the mean (95% CI). Hb, hemoglobin. 2 n = 288. 3 n = 295.
Figure 1Kernel density plots illustrating the distribution of hemoglobin concentrations among: (a) children with HbAA (n = 250), HbAS (n = 40), and Hb SS (n = 5) genotypes; and (b) among children with none (n = 190; α α/α α), one (n = 89; α–/α α), or two (n = 9; α–/α–) alpha-globin deletions.
Simple and multiple regression models of predictors of Hb concentration and anemia 1.
| Independent Variables | Dependent Variable: Hb Concentration (g/L2) | Dependent Variable: Anemia (Hb < 110 g/L) | ||||||
|---|---|---|---|---|---|---|---|---|
| Bivariate Relationships | Adjusted Model | Bivariate Relationships | Adjusted Model | |||||
| β (SE) |
| β (SE) |
| OR (95% CI) |
| OR (95% CI) |
| |
| Age, months | 25.4 (14.4) | 0.088 | 24.7 (11.0) | 0.033 | 0.972 (0.949–0.997 | 0.026 | 0.963 (0.938–0.990) | 0.007 |
| Male | −598 (331) | 0.080 | -- | 0.25 | 0.76 (0.45–1.28) | 0.30 | -- | 0.48 |
| Hb AS | −138 (368) | 0.71 | -- | 0.15 | 2.01 (1.01–4.02) | 0.047 | 2.14 (1.13–4.07) | 0.020 |
| Hb SS | −6960 (1020) | <0.0001 | −6790 (880) | <0.0001 | >999 (>999–>999) 5 | <0.0001 | >999 (>999–>999) | <0.001 |
| α+thalassemia heterozygote | −149 (341) | 0.67 | -- | 0.31 | 0.81 (0.46–1.42) | 0.47 | -- | 0.71 |
| α+thalassemia homozygote | −1470 (490) | 0.006 | −1270 (440) | 0.007 | 4.31 (1.03–17.93) | 0.045 | -- | 0.11 |
| Malaria | −2050 (690) | 0.006 | −1760 (620) | 0.008 | 2.62 (1.10–6.27) | 0.030 | 2.80 (1.03–7.64) | 0.045 |
| Adjusted RBP 3 < 0.83 µmol/L | −1360 (430) | 0.004 | −620 (299) | 0.048 | 2.00 (1.09–3.67) | 0.026 | -- | 0.13 |
| Adjusted ferritin 3 < 12 µg/L | −1270 (310) | 0.0003 | −1170 (330) | 0.001 | 2.46 (1.38–4.41) | 0.002 | 2.08 (1.03–4.17) | 0.040 |
| Low adjusted plasma zinc 3,4 | −425 (399) | 0.30 | -- | 0.99 | 1.26 (0.68–2.32) | 0.46 | -- | 0.90 |
| Plasma CRP, mg/L | −334 (129) | 0.015 | -- | 0.71 | 1.05 (1.01–1.09) | 0.015 | 1.05 (1.01–1.09) | 0.014 |
| Plasma AGP, g/L | −1520 (550) | 0.010 | −1290 (470) | 0.010 | 2.46 (1.16–5.21) | 0.019 | -- | 0.44 |
| Plasma folate, nmol/L | 18.4 (8.1) | 0.03 | -- | 0.27 | 0.975 (0.962–0.989) | 0.0003 | 0.976 (0.961–0.991) | 0.002 |
| Plasma vitamin B12, pmol/L | 1.45 (0.38) | 0.0007 | 0.984 (0.312) | 0.004 | 0.999 (0.998–1.000) | 0.012 | -- | 0.078 |
1 Analysis conducted using SAS PROC SURVEYREG and SURVEYLOGISTIC, for hemoglobin concentration (n = 266; R2 = 0.34 for final model) and anemia (n = 273 for final model), respectively. AGP, α1-acid glycoprotein; CRP, C-reactive protein; Hb, hemoglobin; OR, odds ratio. 2 For variables removed from the model, p-values indicate the adjusted p-value at the step at which the variable was removed from the model. For variables retained in the final model, the p-value reflects the final adjusted model (with all non-significant variables removed). 3 Values adjusted for inflammation by regression analysis to values equivalent to those at CRP and AGP concentrations of 0.14 mg/L CRP and 0.52 g/L AGP (the 10th percentile among individuals with CRP < 5 and AGP < 1). 4 Low plasma zinc defined as <65 µg/dL for AM samples and < 57 µg/dL for PM samples [23], after adjusting for inflammation as noted above. 5 All children with the HbSS genotype were anemic.
Characteristics associated with elevated sTfR among children 12–59 months of age in Yaoundé and Douala, Cameroon.
| sTfR ≤ 8.3 mg/L | sTfR > 8.3 mg/L |
| |
|---|---|---|---|
| 211–221 | 72–76 | ||
| Age, months | 34.3 ± 1.0 | 29.9 ± 1.5 | 0.014 |
| Male, % | 46.6 ± 3.2 | 64.1 ± 5.9 | 0.012 |
| Hemoglobin, g/L | 112 ± 1 | 102 ± 2 | <0.001 |
| Anemic, % | 37.3 ± 3.1 | 69.4 ± 4.5 | <0.001 |
| Malaria, % | 5.1 ± 1.7 | 18.9 ± 5.5 | 0.0005 |
| Reticulocytes, cells/nL | 38.8 ± 1.6 | 68.4 ± 6.3 | <0.001 |
| Reticulocytes > 150 cells/nL, % | 0 | 6.8 ± 2.9 | <0.001 |
| Inflammation (CRP > 5 mg/L and/or AGP > 1 g/L) | 42.1 ± 3.1 | 59.3 ± 5.6 | 0.002 |
| CRP, mg/L | 4.23 ± 0.49 | 5.31 ± 1.01 | 0.31 |
| AGP, mg/L | 0.94 ± 0.02 | 1.06 ± 0.04 | 0.003 |
| Adjusted ferritin 2 < 12 µg/dL, % | 6.3 ± 1.6 | 33.5 ± 6.8 | <0.001 |
| Adjusted RBP 2 < 0.83 µmol/L, % | 11.7 ± 2.2 | 18.5 ± 4.7 | 0.18 |
| Low adjusted zinc 2,3, % | 21.5 ± 3.8 | 25.8 ± 5.8 | 0.38 |
| Plasma folate, nmol/L | 56.7 ± 2.4 | 54.3 ± 2.7 | 0.44 |
| Plasma vitamin B12, pmol/L | 828 ± 30 | 778 ± 84 | 0.54 |
| HbAS genotype | 13.0 ± 2.1 | 16.2 ± 4.8 | 0.52 |
| HbSS genotype | 0 | 6.3 ± 2.7 | <0.001 |
| α+thalassemia heterozygote | 31.8 ± 2.9 | 27.7 ± 4.5 | 0.44 |
| α+thalassemia homozygote | 2.4 ± 1.0 | 5.4 ± 2.4 | 0.17 |
1 Values are mean or % ± SE. AGP, alpha-1-acid glycoprotein; BIS, body iron stores; CRP, C-reactive protein; Hb, hemoglobin; RBP, retinol-binding protein; sTfR, soluble transferrin receptor. 2 Values adjusted for inflammation by regression analysis to values equivalent to those at CRP and AGP concentrations of 0.14 mg/L CRP and 0.52 g/L AGP (the 10th percentile among individuals with CRP < 5 and AGP < 1). 3 Low plasma zinc defined as <65 µg/dL for AM samples and <57 µg/dL for PM samples [23], after adjusting for inflammation as noted above.